{
  "study_id": "ISRCTN 12808747",
  "study_title": "Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both",
  "table_name": "Table S1",
  "table_title": "Summary characteristics of participants included in the economic evaluation (n=707) and all study participants (n=757)",
  "description": "Baseline characteristics for two patient cohorts: those included in the economic analysis subset and all participants in the TRAPEZE trial.",
  "footnotes": [],
  "groups": [
    {
      "name": "Economic analysis subset",
      "n": 707,
      "type": "analysis set"
    },
    {
      "name": "All TRAPEZE trial participants",
      "n": 757,
      "type": "total population"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age median (IQR)",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "numeric_median_iqr",
          "median": 68.0,
          "iqr_min": 64.0,
          "iqr_max": 73.0,
          "raw_string": "68 (64, 73)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "numeric_median_iqr",
          "median": 68.0,
          "iqr_min": 63.0,
          "iqr_max": 73.0,
          "raw_string": "68 (63, 73)"
        }
      ]
    },
    {
      "original_label": "PSA median (IQR)",
      "standardized_name": "Prostate-specific antigen",
      "category": "Biomarker",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "numeric_median_iqr",
          "median": 143.75,
          "iqr_min": 49.8,
          "iqr_max": 347.6,
          "raw_string": "143.75 (49.8, 347.6)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "numeric_median_iqr",
          "median": 145.55,
          "iqr_min": 51.2,
          "iqr_max": 353.58,
          "raw_string": "145.55 (51.2, 353.58)"
        }
      ]
    },
    {
      "original_label": "Prior Radiotherapy n (%)",
      "standardized_name": "Prior Radiotherapy",
      "category": "Medical History",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "categorical_count_percentage",
          "count": 331.0,
          "percentage": 44.3,
          "raw_string": "331 (44.30%)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "categorical_count_percentage",
          "count": 337.0,
          "percentage": 44.87,
          "raw_string": "337 (44.87%)"
        }
      ]
    },
    {
      "original_label": "Daily Present Pain Index (scale 0.5) median (IQR)",
      "standardized_name": "Daily Present Pain Index",
      "unit": "score",
      "category": "Clinical Assessment",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "numeric_median_iqr",
          "median": 1.43,
          "iqr_min": 0.86,
          "iqr_max": 2.0,
          "raw_string": "1.43 (0.86, 2.00)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "numeric_median_iqr",
          "median": 1.43,
          "iqr_min": 0.86,
          "iqr_max": 2.0,
          "raw_string": "1.43 (0.86, 2.00)"
        }
      ]
    },
    {
      "original_label": "Daily Analgesic Score median (IQR)",
      "standardized_name": "Daily Analgesic Score",
      "unit": "score",
      "category": "Clinical Assessment",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "numeric_median_iqr",
          "median": 10.01,
          "iqr_min": 0.86,
          "iqr_max": 27.63,
          "raw_string": "10.01 (0.86, 27.63)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "numeric_median_iqr",
          "median": 10.21,
          "iqr_min": 0.88,
          "iqr_max": 27.89,
          "raw_string": "10.21 (0.88, 27.89)"
        }
      ]
    },
    {
      "original_label": "ECOG n(%)",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Assessment",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "header",
          "raw_string": "ECOG n(%)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "header",
          "raw_string": "ECOG n(%)"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status 0",
      "category": "Clinical Assessment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "categorical_count_percentage",
          "count": 291.0,
          "percentage": 41.16,
          "raw_string": "291 (41.16)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "categorical_count_percentage",
          "count": 305.0,
          "percentage": 40.29,
          "raw_string": "305 (40.29)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status 1",
      "category": "Clinical Assessment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "categorical_count_percentage",
          "count": 361.0,
          "percentage": 51.06,
          "raw_string": "361 (51.06)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "categorical_count_percentage",
          "count": 389.0,
          "percentage": 51.39,
          "raw_string": "389 (51.39)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status 2",
      "category": "Clinical Assessment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Economic analysis subset",
          "data_type": "categorical_count_percentage",
          "count": 55.0,
          "percentage": 7.78,
          "raw_string": "55 (7.78)"
        },
        {
          "group_name": "All TRAPEZE trial participants",
          "data_type": "categorical_count_percentage",
          "count": 63.0,
          "percentage": 8.32,
          "raw_string": "63 (8.32)"
        }
      ]
    }
  ]
}
